Mauro G. Bavetta
Frascati, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Psoriasis and Emotional Dysregulation: A Multicenter Analysis of Psychodermatology Outcomes.
Journal: Dermatology practical & conceptual
Published: December 27, 2024
Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real-world study.
Journal: International journal of dermatology
Published: January 17, 2024
Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy.
Journal: Expert opinion on biological therapy
Published: July 19, 2021
A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-naïve patients and in patients undergoing non-medical switch from originator.
Journal: Current medical research and opinion
Published: May 20, 2021
The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions.
Journal: Journal of clinical medicine
Published: November 26, 2020
A linear forehead lesion caused by intralesional injection of triamcinolone acetonide and treated with hyaluronic acid filler: Case report.
Journal: Dermatologic therapy
Published: July 08, 2020
Skin advanced glycation end products as a diagnostic and monitoring tool among psoriatic patients: how the therapy helps reduce cardiovascular disease risk.
Journal: International journal of dermatology
Published: June 25, 2020
Risankizumab: How to choose the right dose in clinical practice?
Journal: Dermatologic therapy
Published: June 07, 2020
Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma.
Journal: The Journal of dermatological treatment
Published: May 19, 2020
Ixekizumab: One drug for an enigmatic psoriasis.
Journal: Dermatologic therapy
Published: April 10, 2020
Last Updated: 09/26/2026